Reggio Calabria

• PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending
  2024-514355-16-01 5 Acute Respiratory Distress Syndrome (ARDS)
• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 4 newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
• Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell … Pending
  2024-520326-11-00 4 Acute Myeloid Leukemia (AML)
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly … Pending
  2025-521827-61-00 4 refractory/relapsed multiple myeloma
• Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed afte … Pending
  2025-523428-39-00 4 Mantle Cell Lymphoma
• Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC … Pending
  2025-523448-10-00 4 Gvhd Resistant to ruxolitinib and steroids
• A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipien … Recruiting
  2025-521074-34-00 4 2026-05-15 Allogeneic peripheral hematopoietic stem cell transplant
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• A Study of AG-946 in Participants With Anaemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS). Recruiting
  2022-500609-42-00 4 2023-02-24 Anemia Due to Lower-Risk Myelodysplastic Syndromes
• A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing … Recruiting
  2024-512752-38-00 5 2025-09-09 Adjunctive and maintenance treatment to HCT
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME … Recruiting
  2024-512696-12-00 4 2025-06-24 BCR-ABL1+ Chronic Myeloid Leukemia
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting
  2024-515252-20-00 9 2025-03-14 Myelofibrosis (MF) unresponsive to JAK inhibitors
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes. Recruiting
  2024-520133-72-00 4 2025-02-05 Myelodysplastic syndromes
• Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting
  2024-519310-31-00 4 2025-01-27 Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
• MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M … Recruiting
  2024-516841-38-00 4 2025-01-09 recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia

Showing 1–24 of 65 trials